Satralizumab
Enspryng (satralizumab) is an antibody pharmaceutical. Satralizumab was first approved as Enspryng on 2020-08-14. It is used to treat neuromyelitis optica in the USA. It has been approved in Europe to treat neuromyelitis optica.
| Trade Name | Enspryng |
|---|---|
| Common Name | Satralizumab |
| Indication | neuromyelitis optica |
| Drug Class | Monoclonal antibodies: humanized, immunomodulating |
